Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Neil Tanday

Showing results (1-10 of 27) with videos related to

Pageof 3
Sort By:
Diabetic Medicine : a Journal of the British Diabetic Association|September 25, 2021
Amplifying the antidiabetic actions of glucagon-like peptide-1: Potential benefits of new adjunct therapiesNeil Tanday, Peter R Flatt, Nigel Irwin
British Journal of Pharmacology|April 6, 2021
Metabolic responses and benefits of glucagon-like peptide-1 (GLP-1) receptor ligandsNeil Tanday, Peter R Flatt, Nigel Irwin
International Journal of Molecular Sciences|May 14, 2025
The Beneficial Impact of a Novel Pancreatic Polypeptide Analogue on Islet Cell LineageWuyun Zhu, Neil Tanday, Peter R Flatt, et al.
Peptides|December 12, 2022
Pancreatic polypeptide revisited: Potential therapeutic effects in obesity-diabetesWuyun Zhu, Neil Tanday, Peter R Flatt, et al.
Biochimica Et Biophysica Acta. General Subjects|February 3, 2020
Development and characterisation of a peptidergic N-and C-terminally stabilised mammalian NPY1R agonist which protects against diabetes inductionRyan A Lafferty, Neil Tanday, Peter R Flatt, et al.
Diabetes, Obesity & Metabolism|July 18, 2022
Beneficial metabolic effects of recurrent periods of beta-cell rest and stimulation using stable neuropeptide Y1 and glucagon-like peptide-1 receptor agonistsNeil Tanday, Ryan A Lafferty, Peter R Flatt, et al.
Metabolism: Clinical and Experimental|August 11, 2020
Generation and characterisation of C-terminally stabilised PYY molecules with potential in vivo NPYR2 activityRyan A Lafferty, Neil Tanday, Peter R Flatt, et al.
Biochemical Pharmacology|May 4, 2020
Dapagliflozin exerts positive effects on beta cells, decreases glucagon and does not alter beta- to alpha-cell transdifferentiation in mouse models of diabetes and insulin resistanceNeil Tanday, Nigel Irwin, Peter R Flatt, et al.
The Journal of Endocrinology|January 25, 2020
Liraglutide and sitagliptin counter beta- to alpha-cell transdifferentiation in diabetesNeil Tanday, Peter R Flatt, Nigel Irwin, et al.
Frontiers in Endocrinology|May 31, 2021
Benefits of Sustained Upregulated Unimolecular GLP-1 and CCK Receptor Signalling in Obesity-DiabetesNeil Tanday, Andrew English, Ryan A Lafferty, et al.
Pageof 3

Showing results (1-10 of 27) with videos related to

Sort By:
Pageof 3
Diabetic Medicine : a Journal of the British Diabetic Association|September 25, 2021
Amplifying the antidiabetic actions of glucagon-like peptide-1: Potential benefits of new adjunct therapiesNeil Tanday, Peter R Flatt, Nigel Irwin
British Journal of Pharmacology|April 6, 2021
Metabolic responses and benefits of glucagon-like peptide-1 (GLP-1) receptor ligandsNeil Tanday, Peter R Flatt, Nigel Irwin
International Journal of Molecular Sciences|May 14, 2025
The Beneficial Impact of a Novel Pancreatic Polypeptide Analogue on Islet Cell LineageWuyun Zhu, Neil Tanday, Peter R Flatt, et al.
Peptides|December 12, 2022
Pancreatic polypeptide revisited: Potential therapeutic effects in obesity-diabetesWuyun Zhu, Neil Tanday, Peter R Flatt, et al.
Biochimica Et Biophysica Acta. General Subjects|February 3, 2020
Development and characterisation of a peptidergic N-and C-terminally stabilised mammalian NPY1R agonist which protects against diabetes inductionRyan A Lafferty, Neil Tanday, Peter R Flatt, et al.
Diabetes, Obesity & Metabolism|July 18, 2022
Beneficial metabolic effects of recurrent periods of beta-cell rest and stimulation using stable neuropeptide Y1 and glucagon-like peptide-1 receptor agonistsNeil Tanday, Ryan A Lafferty, Peter R Flatt, et al.
Metabolism: Clinical and Experimental|August 11, 2020
Generation and characterisation of C-terminally stabilised PYY molecules with potential in vivo NPYR2 activityRyan A Lafferty, Neil Tanday, Peter R Flatt, et al.
Biochemical Pharmacology|May 4, 2020
Dapagliflozin exerts positive effects on beta cells, decreases glucagon and does not alter beta- to alpha-cell transdifferentiation in mouse models of diabetes and insulin resistanceNeil Tanday, Nigel Irwin, Peter R Flatt, et al.
The Journal of Endocrinology|January 25, 2020
Liraglutide and sitagliptin counter beta- to alpha-cell transdifferentiation in diabetesNeil Tanday, Peter R Flatt, Nigel Irwin, et al.
Frontiers in Endocrinology|May 31, 2021
Benefits of Sustained Upregulated Unimolecular GLP-1 and CCK Receptor Signalling in Obesity-DiabetesNeil Tanday, Andrew English, Ryan A Lafferty, et al.
Pageof 3